Copeptin in the Diagnosis of Post-operative Insipidus Diabetes After Pituitary Surgery
NCT ID: NCT04326569
Last Updated: 2024-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
57 participants
INTERVENTIONAL
2022-01-03
2024-03-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Central diabetes insipidus is a frequent complication of endoscopic trans-sphenoidal pituitary endoscopic surgery, with a prevalence of up to 30% of cases. It is the consequence of insufficient secretion of the anti-diuretic hormone arginine vasopressin (AVP) by the posterior pituitary (Melmed et al, 2017).
In the absence of specific treatment, diabetes insipidus can lead to severe ionic and osmotic disorders, mainly acute dehydration with the risk of severe consequences particularly neurological.
Monitoring for the appearance of diabetes insipidus is therefore necessary from the immediate post-operative period.
To date, diabetes insipidus is initially suspected before the appearance of major polyuria. Several biological assays (urinary density, natraemia, urinary osmolarity and plasma) can help to confirm the diagnosis, but the sensitivity and specificity of these biomarkers remains quite low for this indication.
The determination of MVA is difficult because this hormone is unstable ex vivo. To date, its use in current practice remains complicated.
MVA and copeptin are derived from the same precursor and are therefore co-secreted by the pituitary gland in equimolar proportions.
Copeptin has a relatively short in vivo half-life of about 25 minutes, as does MVA, but is more stable in vitro when blood has been drawn.
Its use in the early diagnosis of diabetes insipidus after pituitary surgery could therefore be of interest.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Corticotropin Releasing Hormone (CRH) on the Sleep in Patients With Hypopituitarism
NCT00666068
Hormone Deficiency After Brain Injury During Combat
NCT01666964
Sleep Disorders in Hypothalamic and Pituitary Damage
NCT07143266
Hyperprolactinaemia Management in Reproductive Services at University Hospital of Coventry and Warwickshire
NCT03569787
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure
NCT00133783
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
adults with trans-sphenoidal endoscopic pituitary surgery
adult with trans-sphenoidal endoscopic pituitary surgery for tumour of the sellar region
Blood sample
Blood sample to quantify copeptin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sample
Blood sample to quantify copeptin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
exclusion criteria : Patient with preoperative diabetes insipidus. Patient undergoing pituitary surgery for suspicion of craniopharyngioma Patient undergoing pituitary surgery for pituitary metastases Patient under 18 years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CHU de Reims
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Damien JOLLY
Reims, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PA20033
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.